Novo Nordisk and Aspect Biosystems are entering a new phase of their partnership focused on the development of advanced cell-based medicines for the treatment of diabetes.[1][2] The partnership began in 2023 and now includes the integration of selected Novo Nordisk technologies into the Aspect Biosystems platform in Canada.[1][2] Aspect Biosystems will acquire the rights to technologies related to islet-derived stem cells and hypoimmune cells and will lead the development, manufacture and commercialization of these drugs.[3][4] Novo Nordisk will provide additional investment and research funding, with the option to expand the role in later stages of development and commercialization.[2][4] Cell-based drugs are designed to be allogeneic, allowing for scalable production from off-the-shelf cells, with the goal of restoring blood sugar control in patients with type 1 diabetes without the need for chronic immunosuppression.[1][5] This collaboration combines Novo Nordisk's century-long expertise in the fight against diabetes with Aspect Biosystems' bioprinting technology.[1][4]